Asahi Kasei Life Science Corporation / The Noguchi Institute
2026 · Licensing/Option · Complete
Announcement Sentiment
50
Neutral / mixed
Asahi Kasei Life Science licensed a novel antibody-drug conjugate technology from The Noguchi Institute that enables precise control over drug-to-antibody ratio and attachment site for single- and dual-payload ADCs. The partners will advance commercialization of ADC drug platforms including potential sub-licensing to biopharma companies and CDMOs such as Asahi Kasei subsidiary Bionova Scientific, with financial terms undisclosed.